CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, apoptosis and migration

The coiled coil is a superhelical structural protein motif involved in a diverse array of biological functions, and the abnormal expression of the coiled-coil domain containing proteins has a direct link with the phenotype of tumor cell migration, invasion and metastasis. The aim of this study was to investigate the critical role of Coiled-coil domain-containing protein 34 (CCDC34) in bladder carcinogenesis, which has never been reported to date. Here, we found CCDC34 expression was elevated in bladder cancer tissues and cell lines. The knockdown of CCDC34 via lentivirus-mediated siRNA significantly suppressed bladder cancer cells proliferation and migration, and induced cell cycle arrest at G2/M phase and increased apoptosis in vitro. In addition, CCDC34 knockdown suppressed bladder tumor growth in nude mice. Moreover, CCDC34 silencing decreased the phosphorylation of MEK, ERK1/2, JNK, p38 and Akt, and the expressions of c-Raf and c-Jun, indicating MAPK and AKT pathways (ERK/MAPK, p38/MAPK, JNK/MAPK and PI3K/Akt) might be involved in CCDC34 regulation of bladder cancer cell proliferation and migration. Our findings revealed for the first time a potential oncogenic role for CCDC34 in bladder carcinoma pathogenesis and it may serve as a biomarker or even a therapeutic target for bladder cancer.

[1]  C. Cordon-Cardo,et al.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. , 2007, The Journal of clinical investigation.

[2]  Junjie Chen,et al.  CCDC98 is a BRCA1-BRCT domain–binding protein involved in the DNA damage response , 2007, Nature Structural &Molecular Biology.

[3]  S. Koul,et al.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors. , 2013, Genes & cancer.

[4]  Ming Chen,et al.  CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells. , 2009, Carcinogenesis.

[5]  Masayuki Takahashi,et al.  Role of phosphatidylinositol‐3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor‐related apoptosis‐inducing ligand , 2006, Cancer science.

[6]  H. Nothwang,et al.  Cloning and characterization of the breakpoint regions of a chromosome 11;18 translocation in a patient with hamartoma of the retinal pigment epithelium , 2001, Cytogenetic and Genome Research.

[7]  L. Kiemeney,et al.  Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.

[8]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[9]  D. Zhang,et al.  Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells , 2009, Oncogene.

[10]  J. Stetefeld,et al.  The use of coiled-coil proteins in drug delivery systems , 2009, European Journal of Pharmacology.

[11]  Junxia Chen,et al.  Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. , 2014, Cellular signalling.

[12]  M. Caraglia,et al.  Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells , 2013, Cell Death and Disease.

[13]  Li Lin,et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. , 2011, Cancer cell.

[14]  CCDC134 is down-regulated in gastric cancer and its silencing promotes cell migration and invasion of GES-1 and AGS cells via the MAPK pathway , 2012, Molecular and Cellular Biochemistry.

[15]  Oh-Hyung Kwon,et al.  Epigenetic alteration of CCDC67 and its tumor suppressor function in gastric cancer. , 2012, Carcinogenesis.

[16]  B. Jiang,et al.  PI3K/PTEN signaling in angiogenesis and tumorigenesis. , 2009, Advances in cancer research.

[17]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[18]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[19]  T. Pawson,et al.  The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner , 2014, Oncogene.

[20]  S. Novaković,et al.  KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study , 2012, BMC Cancer.

[21]  Y. Lei,et al.  Mitogen-activated protein kinase signal transduction in solid tumors. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[22]  Eytan Domany,et al.  Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancer , 2009, Proceedings of the National Academy of Sciences.

[23]  A. Cheung,et al.  PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma , 2015, Oncotarget.

[24]  J. Hou,et al.  Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. , 2013, The Journal of urology.

[25]  Zhen Liu,et al.  Decreased expression of updated NESG1 in nasopharyngeal carcinoma: Its potential role and preliminarily functional mechanism , 2011, International journal of cancer.

[26]  M. Islam,et al.  Expression of the coiled coil domain containing protein 116 in the pancreatic islets and endocrine pancreatic tumors , 2012, Islets.